Navigation Links
Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Date:6/21/2013

retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:

Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com 



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering
2. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
3. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
4. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
5. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
6. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
7. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
8. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
9. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
10. Oramed Submits New IND Application for Oral Insulin Trial in the US
11. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... a leading Clinical Research Organization, announces it is ... World (ECDW), 13-14 May 2009, in London, UK. ... and most highly regarded early development congress. Experts ... be available to discuss PRA,s capabilities at ECDW. ...
... 11 Arno Therapeutics, Inc., a clinical-stage biopharmaceutical ... the U.S. Food and Drug Administration ("FDA") accepted ... the use of AR-12, a potentially first-in-class, orally ... and induces the endoplasmic reticulum stress pathway. ...
Cached Medicine Technology:PRA International: Participating Sponsor for Exploratory Clinical Development World in London 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3
(Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
(Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
(Date:7/12/2014)... 2014 Recently, iFitDress.com, one of the world’s ... red evening gowns . What’s more, all these hot ... , The company’s senior spokesman states, “We are proud to ... website is an enjoyable shopping experience. In addition to the ... store, low prices do not always mean bad quality. All ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... Stiefel Laboratories, Inc.,("Stiefel Laboratories"), the world,s ... today that the waiting,period under the Hart-Scott-Rodino ... Act") has expired, for its proposed acquisition ... BTRX )., As previously announced, Stiefel ...
... of Adelaide have developed a novel approach to treating ... fewer side effects. , Professor Wayne Tilley and Dr ... Research Laboratories have discovered that by using existing prostate ... doses, they can expect to generate better results for ...
... smoking spouse quits , , TUESDAY, July 29 (HealthDay News) -- ... risk for experiencing a stroke, a new study suggests. , ... who still smoke carry an even greater risk for stroke. ... bear any higher risk for stroke than those married to ...
... Southern Home Medical,Equipment, Inc. (OTC: SHOM) announced today ... solid growth. Industry statistics,suggest a very favorable market ... from the U.S. Bureau of Labor Statistics published ... one million new and,replacement nurses will be needed ...
... for Excellence Issue Brief, WASHINGTON, July 29 ... has issued its second issue brief on retiree,health ... Estimates,of Liabilities. The brief, which was written by ... and entrepreneurship in the,College of Management, North Carolina ...
... single women identify any gaps in coverage or inadequate protection ... ... 2008 -- http://www.combinedinsurance.com/ [Combined Insurance], a leading provider ... 27-August 2, 2008, sponsored by SWWAN® (Single Working Women,s Affiliate ...
Cached Medicine News:Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 2Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 3Health News:Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. 4Health News:New treatment for advanced prostate cancer 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 2Health News:Secondhand Smoke Raises Stroke Risk for Spouses 3Health News:Southern Home Medical's Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry 2Health News:Financing Retiree Health Care: Assessing GASB 45 Estimates of Liabilities 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 2Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 3Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 4Health News:Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage 5
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: